These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33618076)

  • 1. Expectations about treatment of idiopathic pulmonary fibrosis: Comparative survey of patients, carers and physicians (the RESPIR French survey).
    Cottin V; Bergot E; Bourdin A; Nunes H; Prévot G; Wallaert B; Marchand-Adam S
    Respir Med Res; 2021 May; 79():100811. PubMed ID: 33618076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis.
    LaCamera PP; Limb SL; Haselkorn T; Morgenthien EA; Stauffer JL; Wencel ML
    Chron Respir Dis; 2019; 16():1479973119879678. PubMed ID: 31558049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I-PreFer Study: A Questionnaire to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Treatment Options.
    Hollmen M; Bromilow T; Smith AB; Mealing S; Lewis D; Galvin L; Jones S; Pacheco L; Soulard S; Froidure A
    Patient Prefer Adherence; 2023; 17():1621-1639. PubMed ID: 37560148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.
    Maher TM; Swigris JJ; Kreuter M; Wijsenbeek M; Cassidy N; Ireland L; Axmann J; Nathan SD
    Respiration; 2018; 96(6):514-524. PubMed ID: 30114692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologists.
    Cottin V; Cadranel J; Crestani B; Dalphin JC; Delaval P; Israel-Biet D; Kessler R; Reynaud-Gaubert M; Valeyre D; Wallaert B; Bouquillon B; Cordier JF
    Respir Med; 2014 Jan; 108(1):195-202. PubMed ID: 24361163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers.
    Ramadurai D; Corder S; Churney T; Graney B; Harshman A; Meadows S; Swigris JJ
    Chron Respir Dis; 2019; 16():1479973119858961. PubMed ID: 31288534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey.
    Majewski S; Lewandowska K; Martusewicz-Boros MM; Piotrowski WJ
    Adv Respir Med; 2019; 87(6):221-230. PubMed ID: 31970724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating Idiopathic pulmonary fibrosis guidelines into clinical practice.
    Robalo-Cordeiro C; Morais A
    Pulmonology; 2021; 27(1):7-13. PubMed ID: 32561352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethnographic survey of patients and caregiver's life journey in idiopathic pulmonary fibrosis.
    Ahmed L; Bergot E; Prévot G; Cottin V
    Respir Med Res; 2023 Jun; 83():100955. PubMed ID: 36634553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey.
    Cottin V; Bergot E; Bourdin A; Cadranel J; Camus P; Crestani B; Dalphin JC; Delaval P; Dromer C; Israel-Biet D; Kessler R; Marchand-Adam S; Marquette CH; Prévot G; Reynaud-Gaubert M; Valeyre D; Wallaert B; Bouquillon B; Cordier JF
    ERJ Open Res; 2015 Oct; 1(2):. PubMed ID: 27730153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. I-PreFer Study: A Discrete Choice Experiment to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Pharmacological Treatment Options.
    Hollmen M; Wijsenbeek M; Bromilow T; Smith AB; Mealing S; Lewis D; Galvin L; Jones S; Asijee G; Soulard S; Froidure A
    Patient Prefer Adherence; 2023; 17():1895-1906. PubMed ID: 37560147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streamlining care in cystic fibrosis: survey of otolaryngologist, pulmonologist, and patient experiences.
    Farzal Z; Dean KM; Sreenath SB; Hodge SE; Thorp BD; Ebert CS; Zanation AM; Senior BA; Kimple AJ
    Int Forum Allergy Rhinol; 2020 May; 10(5):591-603. PubMed ID: 31951081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View.
    Akiyama N; Fujisawa T; Morita T; Mori K; Yasui H; Hozumi H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Pain Symptom Manage; 2020 Nov; 60(5):933-940. PubMed ID: 32569830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation.
    Kreuter M; Polke M; Walsh SLF; Krisam J; Collard HR; Chaudhuri N; Avdeev S; Behr J; Calligaro G; Corte T; Flaherty K; Funke-Chambour M; Kolb M; Kondoh Y; Maher TM; Molina Molina M; Morais A; Moor CC; Morisset J; Pereira C; Quadrelli S; Selman M; Tzouvelekis A; Valenzuela C; Vancheri C; Vicens-Zygmunt V; Wälscher J; Wuyts W; Wijsenbeek M; Cottin V; Bendstrup E
    Eur Respir J; 2020 Apr; 55(4):. PubMed ID: 32060068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
    Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Dirksen CD; Kimman ML; Wijsenbeek MS
    Respir Res; 2020 Jul; 21(1):196. PubMed ID: 32703201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America.
    Cherrez-Ojeda I; Cottin V; Calderón JC; Delgado C; Calero E; Simanca-Racines D; Quadrelli S; Cherrez A
    BMC Pulm Med; 2018 Jan; 18(1):5. PubMed ID: 29321018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
    Wencel ML; Haselkorn T; Limb SL; Stauffer JL; Morgenthien E; Raimundo K; LaCamera PP
    Pulm Ther; 2018 Jun; 4(1):103-114. PubMed ID: 32026247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [French practical guidelines for the diagnosis and management of IPF - 2021 update, short version].
    Cottin V; Bonniaud P; Cadranel J; Crestani B; Jouneau S; Marchand-Adam S; Nunes H; Wémeau-Stervinou L; Bergot E; Blanchard E; Borie R; Bourdin A; Chenivesse C; Clément A; Gomez E; Gondouin A; Hirschi S; Lebargy F; Marquette CH; Montani D; Prévot G; Quetant S; Reynaud-Gaubert M; Salaun M; Sanchez O; Trumbic B; Berkani K; Brillet PY; Campana M; Chalabreysse L; Chatté G; Debieuvre D; Ferretti G; Fourrier JM; Just N; Kambouchner M; Legrand B; Le Guillou F; Lhuillier JP; Mehdaoui A; Naccache JM; Paganon C; Rémy-Jardin M; Si-Mohamed S; Terrioux P;
    Rev Mal Respir; 2022 Mar; 39(3):275-312. PubMed ID: 35304014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic testing in interstitial lung disease: An international survey.
    Terwiel M; Borie R; Crestani B; Galvin L; Bonella F; Fabre A; Froidure A; Griese M; Grutters JC; Johannson K; Kannengiesser C; Kawano-Dourado L; Molina-Molina M; Prasse A; Renzoni EA; van der Smagt J; Poletti V; Antoniou K; van Moorsel CHM
    Respirology; 2022 Sep; 27(9):747-757. PubMed ID: 35652243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.